Management Team:

Alan Jernigan, Chief Executive Officer, has over 20 years of success in growing IVD companies through focused business strategy and acquisition. His global experience growing markets rapidly from scratch through successful product development and commercialization has led to several successful exits for shareholders. Mr. Jernigan has held previous senior level positions for such prestigious medical company’s such as One Lambda a leader in transplant diagnostics, where he was their Chief Commercial Officer and helped them grow to eventually be acquired by Thermo Fisher. Among his other accomplishments at Abbott, Idexx, IGEN, and ThromboVision Inc., were the development and launch of over 35 diagnostic solutions, domestically and internationally, for both the human and non-human markets. He has also been a part of early stage companies helping them develop and commercialize novel technologies and products which in turn saw two of these companies reach successful exits and achieve valuable returns for its investors. Alan has earned a reputation as a trusted and respected leader in the diagnostic industry.

Krishna Jayaraman Ph.D. Co-Founder & Chief Technology Officer. Led GMSbiotech as the President & CEO since its inception until Jan 2014. He has 25 years of senior management experience in diagnostic and therapeutic industry including Kodak & Motorola and small biotech companies including Gemini Biotech where he was the founder & CEO. Gemini biotech was acquired by a small public company where he became the Vice Chairman of the Board. He has held Board & Advisory positions in several startup companies. He was a director of R& D at Motorola Biochip Systems and led technology evaluation for acquisitions and led a $30 million dollar R &D collaboration with Hoechst while he was at Triplex Pharmaceuticals. He has published over 45 papers in prestigious journals and has 6 awarded patents to his credit.

Michael Hogan Ph. D., Co-Founder, Chief Scientific Officer and Chairman, Scientific Advisory Board, is an expert in the microarray field.  Prior to GMSbiotech, he has founded three companies that were funded by first-tier venture capital in oligonucleotide therapeutics, microarray and applied genomics arena. He has been Faculty at Princeton, Baylor College of Medicine and The University of Arizona. He has 19 awarded patents, 12 pending patents and 93 publications in biophysics, applied genetics & biotechnology.

Milan Patel, Chief Financial Officer, has over 20 years of experience with large public, to small private and entrepreneurial companies in numerous industries from automotive, technology and government technology services. For the past six years, he served as Chief Financial Officer of 2020 Company, LLC -a leading premier professional services firm that delivered business and technology solutions to the government, in the areas of health, education, and science. Prior to that, Milan worked at Intel Corporation as a Senior Finance Manager in their Technology Manufacturing Group with hands on experience in manufacturing finance, direct and indirect procurement and construction negotiations and spending. Milan has extensive experience in corporate finance, mergers and acquisitions, business strategy and planning, infrastructure and organizational development, and controls, compliance and audit.

Krystylle L. Richardson, BSIE, SSGB, RABQSA Auditor, Vice President of Quality Systems and Regulatory Affairs, is the owner of the G3QARA Group. With 20+ years of quality and regulatory management, engineering, auditing and consulting experience, she has partnered with companies to achieve medical device registration by preparing documentation and technical files for 510k’s, PMA’s and CE Marking of their products through compliance to 21CFR Part 820, MDD, IVDD, ISO 9001 and ISO 13485. Krystylle is a certified auditor, a member of the Regulatory Affairs Professional Society and a Six Sigma Green Belt. Krystylle has conducted training for personnel at all organizational levels, across numerous industries and in 13 countries in Process and Software Validation Master Planning and execution, risk management per ISO 14971, Six Sigma Philosophies and techniques, Cost of Quality, communicating with the FDA regarding 483 observation corrective and preventive actions as well as medical device and vigilance reporting.

Benjamin Aaron Adler Ph.D., J.D., General Counsel and Senior Vice-President of Intellectual Property, Licensing and Strategic Alliance. Dr. Adler maintains a practice limited to the preparation, prosecution, securement, licensing, and litigation of patent applications and patents in biotechnology/molecular medicine, medical devices and computer related technology. Dr. Adler holds a doctorate in molecular pharmacology and law degree from Boston University School of Law.